Michel Reid, Senior Director and Head, Global Demographics & Diversity for GSK, will present on My Living Legacy, created in partnership with the Tigerlily Foundation to empower Black and other BIPOC people to more deeply understand and trust in clinical trials and to consider clinical trials as a possible treatment option for life-threatening diseases like breast cancer. Mr. Reid will also share how GSK partnered with MiOrato ensure that women from underserved communities are represented in clinical trials for Ovarian Cancer by training public health student in socioeconomically disadvantaged neighborhoods to become community health educators. 

The FDA defines a decentralized clinical trial as a clinical investigation where some or all of the trial-related activities occur at a location separate from the investigator’s location. Today’s technologies let Patients remotely engage with trial activities, creating better Patient experiences and letting sponsors execute faster trials – driven by high-quality data. Kelly McKee, Vice President, Decentralized Clinical Trials, for Medidata, will present on how to use decentralized trialsto broaden reach and improve Patient, site and sponsor experiences. Using a case study, Ms. McKee will explore what decentralized clinical trials mean for all stakeholders, including biopharmaceutical companies.

Sunanda Gaur, M.D., Director of the Clinical Research Center at Rutgers Robert Wood Johnson Medical School, will share valuable insights into Rutgers’ four-year study on the long-term and delayed impacts of COVID-19 in children. Encompassing more than 2,000 participants, across 14 sites, Dr. Gaur will discuss Rutgers’ community-facing strategy, including bi-lingual recruitment leads, used for trial enrollment. Additionally, Dr. Gaur will elaborate on the decentralize component of the trial to ensure inclusion of diverse populations.